What's wrong here is TTOO doesn't solve the problem of antibiotic resistance. Yea, it can identify candida, which is fungal, but how about all of the bad bugs that are killing patients in the ICU? No can do. 500 hospitals will not buy a machine that can only ID one bug and not do AST on a same shift basis. Your valuation is limited by their limited market breadth. You short AXDX all you want.
Your analysis fails to consider the likely acquisition by a large pharma player after release of product # 2, respiratory ID /AST with in 6 hours. ( listen to Thursday webcast for product rollout strategy) Sell all you like, you will miss the upside of your life. If you think T2 is the answer you don't know the first thing about HAIs and the pressure to reduce reimbursements from Medicare. BTIG may not understand the market opportunity either; the platform has reach into major vertical hospital markets beside HAIs , or fungal infections, such as neonatal care, monitoring of chemo therapy effectiveness as well as direct from blood. Dig deeper man or lose your butt.
jman, you don't know what you're talking about. Barnes-Jewish St Louis and Denver Health have both published studies on the efficacy of the BACcel platform. You can stay short all you want, but don't try to convince others to join you in your ignorance. And BTW, nobody else can do the ID and antibiotic susceptibility test in less than 6 hours or even 2 days. do some more homework, call your buddy at Citron.